activator

(redirected from Urokinase-Type Plasminogen Activator)
Also found in: Dictionary, Thesaurus, Medical.
Related to Urokinase-Type Plasminogen Activator: Plasminogen activator inhibitor

activator

[′ak·tə‚vād·ər]
(chemistry)
A substance that increases the effectiveness of a rubber vulcanization accelerator; for example, zinc oxide or litharge.
A trace quantity of a substance that imparts luminescence to crystals; for example, silver or copper in zinc sulfide or cadmium sulfide pigments.
(genetics)
A molecule that modifies a repressor in a way that enables it to stimulate operon transcription.
(graphic arts)

catalyst

1. A substance which accelerates a chemical reaction but appears to remain unchanged itself.
2. A hardener that accelerates cure of adhesives either with or without heat. Used primarily with synthetic resins.
References in periodicals archive ?
Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis.
Induction of urokinase-type plasminogen activator by the anthracycline antibiotic in human RC-K8 lymphoma and H69 lung-carcinoma cells.
The serine protease urokinase-type plasminogen activator (uPA) and its inhibitor, plasminogen activator inhibitor type 1 (PAI-1), is one example of potential prognostic breast cancer biomarkers.
Urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA) are serine proteases that catalyse the conversion of a proenzyme, plasminogen, to active plasmin and play important roles in thrombolysis (Blasi et al.
Therefore, the study will serve to evaluate the predictive value of the levels of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in the primary tumor with respect to Docetaxel containing chemotherapy regimens.
Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Cancer marker with sequences of identified peptides Urokinase-type plasminogen activator (11 (a)) ALDPAGNESAYPPNGVECYSCVGLSR CAPGVDVCTEAVGAVETIHGQFSLAVR CNEGPILELENLPQNGR DGVTGPGFTLSGSCCQGSR GCGSGLPGKNDR GCVQDEFCTR GLDLHGLLAFIQLQQCAQDR QGVEHEASRDEEPR SDALQLGLGK SPEEQCLDVVTHWIQEGEEGRPK TDSCQGDSGGPLVCSLQGR Cathepsin-D (14 (a)) AIGAVPLIQGEYMIPCEK AYWQVHLDQVEVASGLTLCK DPDAQPGGELMLGGTDSK EGCEAIVDTGTSLMVGPVDEVR FDGILGMAYPR ISVNNVLPVFDNLMQQK KAYWQVHLDQVEVASGLTLCK LLDIACWIHHK LVDQNIFSFYLSR QPGITFIAAK TMSEVGGSVEDLIAK VGFAEAARL YSQAVPAVTEGPIPEVLK YYTVFDRDNNR Cancer antigen 15.
NSO produced a concentration-dependent inhibition of tissue-type plasminogen activator (t-PA), urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor type 1 (PAI-1).
Overproduction of LR11 protein promotes the enhanced migration of SMCs via the upregulation of urokinase-type plasminogen activator receptor (4, 5).
Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.